Christina Mattina

At the European Respiratory Society Congress, experts explored the critical connections between climate change, respiratory health, and health equity, highlighting the importance of integrated solutions, local action, and education.

Experts at the ERS Congress 2025 highlighted threats to scientific integrity from misinformation, political interference, and predatory publishing in health research.

Experts at European Respiratory Society (ERS) Congress 2025 highlight the critical link between reduced lung function and increased cardiovascular disease risk, urging early intervention and awareness.

There are clear benefits to starting biologic therapy earlier for severe asthma, as well as initiation patterns by ethnicity, according to data at ERS Congress 2025.

Expanding community-based cancer services brings advanced treatments closer to home and addresses social determinants of health, says Kathy Oubre, MS.

Digital health technologies enhance respiratory care through decentralized clinical trials and home monitoring, expanding access and improving patient engagement.

Christopher Carlin, MBChB, PhD, explores the potential of AI-driven insights to enhance COPD care and identify candidates for biologic therapy.

Nerandomilast shows promise in treating progressive pulmonary fibrosis, demonstrating significant benefits in lung function and safety in recent trials.

Research reveals that a high-fruit diet may protect women's lung function from air pollution, according to Pimpika Kaewsri, MSc.

Laxmi Patel explains how providers can meet potential new Medicaid documentation requirements without harming patient access.

Integrating these care services can enhance patient QOL and address unmet needs in serious respiratory illnesses, explains Natasha Smallwood, BMedSci, MBBS, MSc, Monash University.

Artificial intelligence (AI) holds the potential to democratize precision oncology, but it must be implemented thoughtfully.

In a time of skyrocketing oncology drug costs, the role of pharmacists in managing patients’ treatment and keeping care in the outpatient setting is more urgent than ever.

Panelists discussed the ingredients of successful handoffs at the time of cancer diagnosis and ways to collaborate as screening capabilities evolve.

As therapeutic advances enable patients with cancer to live longer, greater attention is needed to support the goal of survivorship, starting at diagnosis.

Children who had chronic, early-onset, nonanterior uveitis were at an increased risk of developing other complications surrounding the eye.

Any potential reduction in access to pre-exposure prophylaxis (PrEP) would increase both cost and the number of diagnoses of HIV.

The Trump administration highlighted a potential autism risk from prenatal acetaminophen use, but studies demonstrate conflicting evidence.

Medicare beneficiaries with near low income struggle most with health care affordability, highlighting gaps in financial assistance programs.

Cemiplimab demonstrated a 56% overall survival rate, making it a potential option for physicians to use for treating non–small cell lung cancer (NSCLC).

New research highlights caregiver perspectives to improve colorectal cancer screening access for individuals with intellectual and developmental disabilities.

Tirzepatide appears more cost-effective than semaglutide for obesity and knee osteoarthritis, though long-term data and patient-centered outcomes remain key.

National survey data show rural residents are less likely to receive colorectal cancer screening, with socioeconomic and structural barriers driving the gap.

Findings from the ROCKET-SHUTTLE trial reveal the benefits of combining the anti-OX40 monoclonal antibody with topical therapies for atopic dermatitis.

The approval allows all patients 12 years and older to use pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection for solid tumor indications approved for intravenous pembrolizumab.

Research shows more than a third of patients with rheumatoid arthritis met criteria for frailty, with prefrailty and robust groups closely following.

Research reveals that patients with both rheumatoid arthritis and MASH cirrhosis face significantly higher cardiovascular risks.

The Oncotype DX 21-gene recurrence score helps guide adjuvant therapy in women with early-stage breast cancer and low genomic risk.

Tirzepatide’s cost-effectiveness provides key evidence for policy makers implementing clinical coverage decisions.

With vaccination rates slipping and new policies emerging, parents need to know what’s changing as kids head back to the classroom.